5,20 0,14 (2,77 %)
Vorbörse: 4:00AM EST
|Dr. Dewan Fazlul Hoque Chowdhury||Chairman, CEO & Pres||103,77k||N/A||1973|
|Mr. Justin Mclarney||Chief Fin. Officer||N/A||N/A||N/A|
|Mr. Christopher J. Avery||VP of Global Bus. Operations||N/A||N/A||1963|
|Mr. Bashir Timol||Chief Bus. Officer & Director||N/A||N/A||1974|
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. It has a license agreement with Healthimation, LLC, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for Type 2 diabetes, prediabetes, and general wellness; the Why WAIT app; and common law trademarks which incorporate the mark WHY WAIT or WHYWAIT and the use of licensed marks. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Nemaura Medical Inc.s ISS Governance QualityScore, Stand 22. Januar 2021, lautet 7. Die grundlegenden Scores sind Audit: 10, Vorstand: 8, Shareholderrechte: 2, Kompensation: 5.